Monitoring of Septic Shock-induced Immunosuppression (IMMUNOSEPSIS 5)
Immunological and Clinical Monitoring of Patients With Septic Shock in Intensive Care Unit : In-depth Immunophenotyping of Circulating Immunoregulatory Cells During Sepsis
Septic syndromes are a major although largely under-recognized health care problem and represent the first cause of mortality in intensive care units (ICU). While it has long been known that sepsis deeply perturbs immune homeostasis by inducing a tremendous systemic inflammatory response, novel findings indicate that sepsis indeed initiates a more complex immune response that varies over time, with the concomitant occurrence of both pro- and anti-inflammatory mechanisms. As a resultant, after a short pro-inflammatory phase, septic patients enter a stage of protracted immunosuppression. This is illustrated in those patients by reactivation of dormant viruses (cytomegalovirus (CMV) or Herpes Simplex Virus (HSV)) or infections due to pathogens, including fungi, which are normally pathogenic solely in immunocompromised hosts. These alterations might be directly responsible for worsening outcome in patients who survived initial resuscitation as nearly all immune functions are deeply compromised. New promising therapeutic strategies are currently emerging from those recent findings such as adjunctive immunostimulation for the most immunosuppressed patients.
Recent studies have described the induction of immunoregulatory cells (of myeloid and lymphoid origin) following septic shock and have revealed a similar induction kinetics across all subpopulations of regulatory cells. Nevertheless, these observations need to be confirmed and linked to the underlying mechanisms responsible for the induction of these cells (notably the activation of the inflammasome pathway), which remain largely unknown.
IMMUNOSEPSIS 5 study will therefore, as part of a prospective observational study involving a large cohort of patients, demonstrate the concurrent induction of all regulatory cell subpopulations following sepsis and the activation of the hyper-inflammatory response, including the inflammasome pathway. The association between these parameters and patient outcomes will also be assessed (death and/or the occurrence of a secondary infection).
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: VENET FABIENNE, Pr
- 전화번호: +33 4 72 11 97 46
- 이메일: fabienne.venet@chu-lyon.fr
연구 연락처 백업
- 이름: SAUNIER Clarisse
- 전화번호: +33 04 27 85 62 64
- 이메일: clarisse.saunier@chu-lyon.fr
연구 장소
-
-
-
Lyon, 프랑스, 69004
- Service d'Anesthésie-Réanimation Groupement Hospitalier Nord Hôpital de la Croix Rousse
-
연락하다:
- DELIGNETTE Marie-Charlotte, Dr
- 전화번호: +33 4 26 10 90 70
- 이메일: marie-charlotte.delignette@chu-lyon.fr
-
Lyon, 프랑스, 69004
- Service de Médecine Intensive - Réanimation (MIR) Groupement Hospitalier Nord Hôpital de la Croix Rousse
-
연락하다:
- BITKER Laurent, Dr
- 전화번호: +33 4 26 10 92 69
- 이메일: laurent.bitker@chu-lyon.fr
-
Lyon, 프랑스, 69437
- Service civilo-militaire d'Anesthésie-Réanimation et Médecine Périopératoire - Groupement Hospitalier Centre
-
연락하다:
- LUKASZEWICZ Anne-Claire, Pr
- 전화번호: +33 4 72 11 96 86
- 이메일: anne-claire.lukaszewicz@chu-lyon.fr
-
Lyon, 프랑스, 69437
- Service de Médecine Intensive - Réanimation (MIR) - Groupement Hospitalier Centre
-
연락하다:
- COUR Martin, Pr
- 전화번호: +33 4 72 11 28 52
- 이메일: martin.cour@chu-lyon.fr
-
Pierre-Bénite, 프랑스, 69495
- Service d'Anesthésie-Réanimation-Médecine Intensive Groupement Hospitalier Sud Hôpital Lyon Sud - Bâtiment 3B
-
연락하다:
- DARGENT Auguste, Dr
- 전화번호: +33 4 78 86 14 76
- 이메일: auguste.dargent@chu-lyon.fr
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Men or women aged 18 years or over
- Hospitalised patients with septic shock that began less than 48 hours prior to screening, defined by:
- the presence of a diagnosed or suspected site of infection requiring microbiological sampling
- the need for vasopressor therapy to maintain a mean arterial pressure ≥ 65 mm Hg
- hyperlactataemia > 2 mmol/L (18 mg/dL) within 24 hours of the start of vasopressor therapy despite adequate fluid resuscitation (30 ml/kg).
- A patient or relative who has been informed of the study protocol and has not objected to participating in the study
Exclusion Criteria:
- Pregnant or breastfeeding women
- People not covered by a social security scheme or similar scheme
- Adults subject to legal guardianship (guardianship, curatorship)
- Patients with a language barrier
- Persons deprived of their liberty by a judicial or administrative decision
- Subjects participating in another interventional research study involving an exclusion period that is still ongoing at the time of pre-inclusion and which, in the investigator's judgement, may interfere with this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Adult patient with septic shock
Additional tubes will be collected for the study at the same time as routine blood sample procedure.
No specific intervention will be performed for this study.
Theses samples will be collected at the following timing : inclusion, J3, J5, J15, J25 (until patient is discharged from intensive care).
|
Four additional tubes will be collected during the blood sample carried out as part of standard of care : a 4 mL EDTA tube, a 2.5 mL heparin tube, a 5 mL CytoChex tube and a 4 mL PAXGENE tube.These samples will be taken at inclusion, J3, J5, J15, J25 (until patient is discharged from intensive care)
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Study of the mechanisms regulating the immune response during septic shock, and in particular study of regulatory cell subpopulations in a large cohort of adult patients with septic shock
기간: Inclusion DAY 1 (within the 48 hours of starting vasopressor therapy) Between DAY 3 and DAY 4 Between DAY 5 and DAY 7 Between DAY 15 and DAY 20 Between DAY 25 and DAY 30
|
Modification of immune parameters compared with normal values in particular proportion of immunoregulatory cells
|
Inclusion DAY 1 (within the 48 hours of starting vasopressor therapy) Between DAY 3 and DAY 4 Between DAY 5 and DAY 7 Between DAY 15 and DAY 20 Between DAY 25 and DAY 30
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 69HCL25_0663
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .